CORCEPT THERAPEUTICS INC Additional Paid in Capital, Common Stock
CORCEPT THERAPEUTICS INC (CORT) had Additional Paid in Capital, Common Stock of $1.05 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-29
- 2026-06-30: Additional Paid in Capital, Common Stock $1.05B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.00B.
- 2025-12-31: Additional Paid in Capital, Common Stock $968.60M.
- 2025-09-30: Additional Paid in Capital, Common Stock $933.61M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.05B 10-Q · filed 2026-07-29 |
| 2026-03-31 | $1.00B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $968.60M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $933.61M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $900.86M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $862.87M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $832.11M 10-K · filed 2026-02-24 |
| 2024-09-30 | $806.32M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $781.01M 10-Q · filed 2024-07-29 |
| 2024-03-31 | $758.24M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $738.51M 10-Q · filed 2024-10-30 |
| 2023-09-30 | $722.40M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $695.72M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $679.85M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $662.34M 10-Q · filed 2023-11-01 |
| 2022-09-30 | $648.83M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $625.98M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $608.72M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $591.35M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $571.38M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $554.15M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $536.36M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $516.14M 10-Q · filed 2021-11-03 |
| 2020-09-30 | $496.49M 10-Q · filed 2020-11-03 |
| 2020-06-30 | $481.71M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $465.53M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $457.06M 10-Q · filed 2020-11-03 |
| 2019-09-30 | $446.61M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $436.62M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $427.32M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $417.23M 10-Q · filed 2019-11-07 |
| 2018-09-30 | $408.15M 10-Q · filed 2018-11-02 |
| 2018-06-30 | $401.01M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $390.95M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $384.07M 10-Q · filed 2018-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |